An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
This study is ongoing, but not recruiting participants.
Massachusetts General Hospital
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Ryan J. Sullivan, MD, Dana-Farber Cancer Institute
First received: March 1, 2010
Last updated: January 2, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|